ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "patient-reported outcome measures"

  • Abstract Number: 834 • 2019 ACR/ARP Annual Meeting

    Implementing Patient-Reported Outcome Measures in Clinical Care: Rheumatologist Perspectives on Opportunities and Challenges

    Shanthini Kasturi1, John Wong 1, Lisa Mandl 2, Timothy McAlindon 3 and Amy LeClair 1, 1Tufts Medical Center, Boston, 2Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY, 3Tufts Medical Center, Boston, MA

    Background/Purpose: There is growing interest in the implementation of patient-reported outcome measures (PROMs) in clinical rheumatology to promote patient-centered care and to meet the mandates…
  • Abstract Number: 2514 • 2019 ACR/ARP Annual Meeting

    Relationships Between Minimal Disease Activity and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies

    Philip Helliwell1, Andrew Bushmakin 2, Dafna Gladman 3, Oliver FitzGerald 4, Lara Fallon 5, Joseph Cappelleri 2, Ming-Ann Hsu 6 and Laura Coates 7, 1University of Leeds, Leeds, United Kingdom, 2Pfizer Inc, Groton, CT, 3University of Toronto, Toronto, ON, Canada, 4University College Dublin, Dublin, Ireland, 5Pfizer Inc, Montreal, QC, Canada, 6Pfizer Inc, Collegeville, PA, 7University of Oxford, Oxford, United Kingdom

    Background/Purpose: PsA is associated with multiple disease domains, requiring the use of different clinical measures and patient-reported outcomes (PROs) to assess improvements in disease activity…
  • Abstract Number: 1644 • 2018 ACR/ARHP Annual Meeting

    Improvement in Morning Stiffness in Subjects with Psa Is Associated with Improvements in Pain, Physical Function, and Patient Global Response to Treatment

    Ana-Maria Orbai1, Jessica Walsh2, Peter Nash3, Lichen Teng4, Benoit Guerette4 and Rieke Alten5, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2University of Utah School of Medicine, Salt Lake City, UT, USA, Salt Lake City, UT, 3University of Queensland, Brisbane, Australia, 4Celgene Corporation, Summit, NJ, 5Schlosspark-Klinik University Medicine, Berlin, Germany

    Background/Purpose: Stiffness is an important component of inflammatory arthritis and plays a role in PsA flare. Patients with inflammatory arthritis report difficulty with activities, “slowing…
  • Abstract Number: 1715 • 2018 ACR/ARHP Annual Meeting

    Safety and Efficacy of Lenabasum in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects

    Robert F. Spiera1, Laura K. Hummers2, Lorinda Chung3, Tracy M. Frech4, Robyn T. Domsic5, Vivien Hsu6, Daniel E. Furst7, Jessica K. Gordon1, Maureen D. Mayes8, Robert W. Simms9, Elizabeth Lee10, Scott Constantine10 and Barbara White10, 1Hospital for Special Surgery, New York, NY, 2Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, 4Division of Rheumatology, University of Utah, Salt Lake City, UT, 5Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, 6Rheumatology, Robert Wood Johnson Medical School, New Brunswick, NJ, 7Pacific Arthritis Associates, Los Angeles; University of California, Los Angeles; University of Washington, Seattle; University of Florence, Italy, Los Angeles, CA, 8Rheumatology, University of Texas McGovern Medical School, Houston, TX, 9Rheumatology, Boston University School of Medicine, Boston, MA, 10Corbus Pharmaceuticals, Inc., Norwood, MA

    Background/Purpose: Lenabasum is a synthetic, non-immunosuppressive, selective cannabinoid receptor type 2 agonist that activates resolution of innate immune responses. Lenabasum had acceptable safety and tolerability,…
  • Abstract Number: 2480 • 2018 ACR/ARHP Annual Meeting

    Patient-Reported Outcome Measures Used in Rheumatoid Arthritis Cohorts and Registries Around the World: An Environmental Scan from the Outcome Measures in Rheumatology Critical Outcomes in Longitudinal Observational Studies Working Group

    Richard Zogala1, Karla Criner2, Maria A. Lopez-Olivo1, Natalia Zamora3, Devesh Rai1, Gregory Pratt4, Jude K. A. des Bordes1, Robin Christensen5 and Maria Suarez-Almazor1, 1Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2Internal Medicine, Baylor College of Medicine, Houston, TX, 3Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, 4Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, 5Department of Rheumatology, Musculoskeletal Statistics Unit: The Parker Institute, Bispebjerg and Frederiksberg Hospital, & Department of Rheumatology, Odense University Hospital, Copenhagen, Denmark

    Background/Purpose: International registries and cohorts could potentially provide long-term data on patient-centered outcomes. In recent years there has been a concerted effort to define a…
  • Abstract Number: 2633 • 2018 ACR/ARHP Annual Meeting

    Disease Activity, Organ Damage and Patient-Reported Outcome Measures in Swedish Patients with Recent-Onset SLE

    Rebecca Heijke1, Mathilda Björk1, Martina Frodlund1, Laura McDonald2, Evo Alemao3 and Christopher Sjöwall1, 1Linköping University, Linköping, Sweden, 2Bristol-Myers Squibb, Uxbridge, United Kingdom, 3Bristol-Myers Squibb, Princeton, NJ

    Background/Purpose: Patient (pt)-reported outcome measures (PROMs) are important to inform shared decision-making between pts with SLE and physicians.1 Established measures of disease activity and organ…
  • Abstract Number: 329 • 2018 ACR/ARHP Annual Meeting

    Use of Inter-Professional Collaboration to Improve Adherence to American College of Rheumatology Recommendations for Use of Disease Activity Measures

    Elisheva Weinberger1, Douglas Einstadter2 and Marina Magrey1, 1Rheumatology, Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, 2Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH

    Background/Purpose:  “Treat to target” is the goal of therapy in the treatment of Rheumatoid Arthritis (RA) based on the 2015 American College of Rheumatology (ACR)…
  • Abstract Number: 549 • 2018 ACR/ARHP Annual Meeting

    Unmet Treat-to-Target Goals with Available Targeted Immunomodulators in the Management of Rheumatoid Arthritis: Real World Evidence from the Corrona Registry

    Dimitrios A. Pappas1,2, Namita Tundia3, Ying Shan2, Heather J Litman2 and Joel Kremer4, 1Columbia University, New York, NY, 2Corrona, LLC, Southborough, MA, 3AbbVie Inc., North Chicago, IL, 4Albany Medical College and the Center for Rheumatology, Albany, NY

    Background/Purpose: Targeted immunomodulators (TIMs) have revolutionized the therapy of RA and made low disease activity (LDA) a realistic goal for patients. Given the multiple therapy…
  • Abstract Number: 892 • 2018 ACR/ARHP Annual Meeting

    Establishing the Minimal Clinically Important Difference (MCID) for the Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL)

    Nicolas Richard1, Nigil Haroon2, George Tomlinson3, Ismail Sari1, Zahi Touma4 and Robert D Inman1, 1Rheumatology, Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada, 2Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada, 4University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: The Ankylosing Spondylitis Quality of Life (ASQoL) is a readable and simple to complete questionnaire relating to health-related quality of life (HRQoL) in subjects…
  • Abstract Number: 1387 • 2018 ACR/ARHP Annual Meeting

    Fatigue in Patients with Rheumatoid Arthritis As Compared to Different Groups of Cancer Patients

    Jens Gert Kuipers1, Michael Koller2, Ulrich Rueffer3, Florian Zeman2, Karolina Mueller4 and Joachim Weis5, 1Clinic for Internal Rheumatology, Red Cross Hospital Bremen, Bremen, Germany, 2Center of Clinical Studies, University Hospital Regensburg, Regensburg, Germany, 3German Fatigue Society, Cologne, Germany, 4Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany, 5University Clinic Centre Freiburg, Freiburg, Germany

    Background/Purpose: Fatigue is a common symptom in patients with rheumatoid arthritis (RA) as well as patients with cancer. Fatigue considerably reduces the quality of life…
  • Abstract Number: 236 • 2017 ACR/ARHP Annual Meeting

    Are Magnetic Resonance Imaging Features of the Hand Associated with Patient Reported Physical Function, Global Assessment of Disease Activity, Pain and Health Related Quality of Life in Rheumatoid Arthritis in Clinical Remission? – Longitudinal Results from an Observational Cohort

    Daniel Glinatsi1, Cecilie Heegaard Brahe2, Merete Lund Hetland1,3,4, Lykke Ørnbjerg1, Simon Krabbe5, Joshua Baker6, Mikael Boesen7, Zoreh Rastiemadabadi8, Lone Morsel-Carlsen8,9, Henrik Rogind1,3, Hanne Slott Jensen10, Annette Hansen11, Jesper Nørregaard12, Søren Jacobsen3,13, Lene Terslev1, Tuan Huynh12, Natalia Manilo14, Dorte Vendelbo Jensen1,15, Jakob M. Møller16, Niels Steen Krogh15 and Mikkel Østergaard1,3,17, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, 2Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Glostrup, Denmark, 3University of Copenhagen, Copenhagen, Denmark, 4The DANBIO Registry, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, 5Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, 6Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, 7Department of Radiology and the Parker institute, Copenhagen University Hospital Frederiksberg, Copenhagen, Denmark, 8Department of Radiology, Copenhagen University Hospital Frederiksberg, Copenhagen, Denmark, 9Department of Radiology, Rigshospitalet, Copenhagen, Denmark, 10Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Frederiksberg, Denmark, Copenhagen, Denmark, 11Department of Rheumatology, Copenhagen University Hospital Gentofte, Copenhagen, Denmark, 12Center for Rheumatology and Spine Diseases, Nordsjællands Hospital, Hillerød, Denmark, 13Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, 14Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Frederiksberg, Copenhagen, Denmark, 15The DANBIO Registry, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, 16Department of Radiology, Copenhagen University Hospital Herlev and Gentofte, Copenhagen, Denmark, 17Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

    Background/Purpose: To assess whether magnetic resonance imaging (MRI) inflammation and damage in the wrist and hand of rheumatoid arthritis (RA) patients are associated with patient-reported…
  • Abstract Number: 892 • 2017 ACR/ARHP Annual Meeting

    Health-Related Quality of Life in Patients with Giant Cell Arteritis Treated with Tocilizumab in a Randomized Controlled Phase 3 Trial

    Vibeke Strand1, Sophie Dimonaco2, Katie Tuckwell2, Micki Klearman3, Neil Collinson2 and John H. Stone4, 1Division of Immunology/Rheumatology, Stanford University, Stanford, CA, 2Roche Products, Ltd., Welwyn Garden City, United Kingdom, 3Genentech, South San Francisco, CA, 4Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

    Background/Purpose: Superior rates of sustained glucocorticoid (GC)–free remission were shown in patients with giant cell arteritis (GCA) treated with weekly (QW) or every-other-week (Q2W) subcutaneous…
  • Abstract Number: 1080 • 2017 ACR/ARHP Annual Meeting

    Electronic Patient Reported Outcomes Increase Pediatric Rheumatology Clinic Operations Efficiency While Increasing Patient and Caregiver Satisfaction

    Y. Ingrid Goh1, Talia Goldberg2, Nicholas Lao3 and Brian M. Feldman4, 1Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3University of Western Ontario, London, ON, Canada, 4Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada

    Electronic Patient Reported Outcomes Increase Pediatric Rheumatology Clinic Operations Efficiency While Increasing Patient and Caregiver SatisfactionBackground/Purpose: Patient reported outcomes (PROs) are powerful tools that facilitate…
  • Abstract Number: 1081 • 2017 ACR/ARHP Annual Meeting

    Improving Patient-Reported Outcomes Collection and Documentation for Patients with Rheumatoid Arthritis at Multilingual, Safety Net Hospital Rheumatology Clinic

    Todd Liou1, Omotoke Odimayomi1, Laura Trupin2, Jinoos Yazdany2 and Mary Margaretten3, 1University of California San Francisco, San Francisco, CA, 2Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, 3Medicine, University of California San Francisco, San Francisco, CA

    Background/Purpose: The Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function-10a (PF10a) survey is a reliable and valid measure of function in patients with rheumatoid arthritis…
  • Abstract Number: 1235 • 2017 ACR/ARHP Annual Meeting

    Perceived Stress and Fatigue in Systemic Lupus Erythematosus

    Patricia P. Katz1, Desiree R Azizoddin2 and Meenakshi Jolly3, 1Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 2Department of Medicine and Behavioral Sciences, Rush University, Chicago, IL, 3Rheumatology, Rush University Medical Center, Chicago, IL

    Background/Purpose: Fatigue is a common and often severe symptom among individuals with systemic lupus erythematosus (SLE). Yet, there is an incomplete understanding of the causes…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology